×
Business / Stock Market

AstraZeneca Seeks Emergency Nod In US For AZD7442 To Prevent Symptomatic COVID-19

Published Oct 05 2021 at 7:03 AM GMT
Business Insider

Business Insider @businessinsider.com

Continue reading at businessinsider.com
Key
Points
  • (AZN) said Tuesday that it has submitted a request to the US Food and Drug Administration for an Emergency Use Authorization for its long-acting antibody combination, AZD7442, for prevention of symptomatic COVID-19.
  • The EUA request filing includes data from PROVENT Phase III trial showing 77% reduction in risk of.
Credit
Tags
Continue reading at businessinsider.com
Trending

Stats

  • Published Oct 5, 2021 7:03 AM GMT